Valneva
Valneva SE is a French specialty vaccine company focused on developing, manufacturing, and commercializing prophylactic vaccines for infectious diseases with significant unmet medical needs. The company produces IXCHIQ (the first single-dose chikungunya vaccine), IXIARO (Japanese encephalitis vaccine), and DUKORAL (cholera vaccine), alongside advancing a Phase 3 Lyme disease vaccine candidate (VLA15) in partnership with Pfizer. Main revenue drivers derive from commercial sales of IXCHIQ, IXIARO, and DUKORAL, research collaboration milestone receipts, and government procurement contracts. Valneva serves international travel clinics, military defense forces, public health authorities, and prescription pharmacies across Europe, North America, and global travel markets. The company holds an innovative market position as a premier pure-play specialty vaccine developer. Headquartered in Saint-Herblain, France, it is listed on Euronext Paris and the Nasdaq Stock Market.
2 of the funds FundTelligence covers report a position in Valneva.
- Legal name
- Valneva SE
- Sector
- Health Care
- Country
- France
- Funds holding it
- 2
Funds holding Valneva
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.05 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.0 % (partially disclosed portfolio, June 2026)